Navigation Sciences Secures $400,000 Grant Round

Navigation Sciences, a clinical-stage company, has raised $400,000 in investment capital from investors. This significant funding announcement underscores the progress of its NaviSci™ System, an innovative technology poised to transform the surgical removal of soft tissue tumors. The NaviSci™ System is designed for the tissue-conserving removal of lung cancer and other soft tissue tumors. It integrates Augmented Reality (AR) and advanced software with surgical instruments, providing surgeons with unprecedented guidance. A key capability is its enablement of real-time in-vivo margin measurement, offering a new level of precision during surgical resection. This technological approach aims to deliver improved surgical outcomes for patients. Its core objectives include reducing recurrence risk and conserving vital lung function, crucial for long-term patient health. Furthermore, the system is intended to shorten hospital length of stay and enhance overall surgical workflow, providing tangible benefits for both patients and healthcare providers. The $400,000 in secured funding will be strategically deployed to propel the NaviSci™ System through its next critical clinical development phases. Navigation Sciences plans to use the capital to support essential research and development efforts, scale its operational capabilities, and strengthen its team, ensuring the technology progresses efficiently towards wider clinical adoption and commercialization. Looking forward, Navigation Sciences intends to leverage this investment to further its mission of delivering cutting-edge solutions that enhance precision in soft tissue tumor removal. The company is committed to transforming surgical oncology by providing tools that improve patient care and outcomes, positioning itself for continued growth in the medical technology sector.